Datopotamab Deruxtecan (Dato-DXd) is composed of the anti-TROP-2 IgG1 monoclonal antibody Datopotamab linked with the topoisomerase I inhibitor exatecan derivative (DXd) via a cleavable tetrapeptide linker, ensuring precise eradication of tumor cells (34). The gene discussed is TACSTD2; the disease is neoplasm.